OxTalks is Changing
On 28th November OxTalks will move to the new Halo platform and will become 'Oxford Events' (full details are available on the Staff Gateway).
There will be an OxTalks freeze beginning on Friday 14th November. This means you will need to publish any of your known events to OxTalks by then as there will be no facility to publish or edit events in that fortnight. During the freeze, all events will be migrated to the new Oxford Events site. It will still be possible to view events on OxTalks during this time.
If you have any questions, please contact halo@digital.ox.ac.uk
Reimagining druggability using chemoproteomic platforms
Join us in person or remotely via Teams
Join in person or via Teams – teams.microsoft.com/l/meetup-join/19%3ameeting_YjIwMDM2MzctNDAxZi00OTE4LWJkYjUtZDExNTI5M2QyOGI2%40thread.v2/0?context=%7b%22Tid%22%3a%22cc95de1b-97f5-4f93-b4ba-fe68b852cf91%22%2c%22Oid%22%3a%22f872a3ea-d819-438d-846a-98171c997249%22%7d
The Nomura Research Group is focused on reimagining druggability using chemoproteomic platforms to develop transformative medicines. One of the greatest challenges that we face in discovering new disease therapies is that most proteins are considered “undruggable,” in that most proteins do not possess known binding pockets or “ligandable hotspots” that small-molecules can bind to modulate protein function. Our research group addresses this challenge by advancing and applying chemoproteomic platforms to discover and pharmacologically target unique and novel ligandable hotspots for disease therapy. We currently have three major research directions. Our first major focus is on developing and applying chemoproteomics-enabled covalent ligand discovery approaches to rapidly discover small-molecule therapeutic leads that target unique and novel ligandable hotspots within undruggable protein targets and pathways. Our second research area focuses on using chemoproteomic platforms to expand the scope of targeted protein degradation technologies. Our third research area focuses on using chemoproteomics-enabled covalent ligand discovery platforms to develop new induced proximity-based therapeutic modalities. Collectively, our lab is focused on developing next-generation transformative medicines through pioneering innovative chemical technologies to overcome challenges in drug discovery.
Date:
23 May 2024, 11:00
Venue:
Pharmacology, off Mansfield Road OX1 3QT
Venue Details:
David Smith Lecture Theatre
Speaker:
Professor Dan Nomura (University of California, Berkeley)
Organising department:
Department of Pharmacology
Organiser:
Carolyn Thackrah (University of Oxford, Department of Pharmacology)
Organiser contact email address:
carolyn.thackrah@pharm.ox.ac.uk
Host:
Dr Thomas Lanyon-Hogg (Career Development Fellow, Department of Pharmcology)
Part of:
Pharmacology, Anatomical Neuropharmacology and Drug Discovery Seminars
Booking required?:
Not required
Audience:
Members of the University only
Editor:
Carolyn Thackrah
